T-cell immunodeficiency with thymic aplasia Advocacy Hub | UniteRare

At a Glance

Live from database

💊

Regulatory Watchboard

1 event

Oct 2021

Rethymic: FDA approved

immune reconstitution in pediatric patients with congenital athymia

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Rethymic

Enzyvant Therapeutics GmbH

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Rethymic

(allogeneic processed thymus tissue-agdc)Orphan drug

Enzyvant Therapeutics GmbH

12.1 Mechanism of Action RETHYMIC is intended to reconstitute immunity in patients who are athymic. The proposed mechanism of action involves the migr...

Approved Oct 2021FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for T-cell immunodeficiency with thymic aplasia.
Search all trials →

Search clinical trials for T-cell immunodeficiency with thymic aplasia →

Recent News & Research

No recent news articles indexed yet for T-cell immunodeficiency with thymic aplasia.
Search PubMed for T-cell immunodeficiency with thymic aplasia →

Browse all T-cell immunodeficiency with thymic aplasia news →

Specialist Network

Top 2 by expertise

M. Louise Markert, MD, PhD

Duke University Medical Center, Pediatrics, Allergy & Immunology

Score 105 trials

John W. Sleasman, M.D., MD

Duke University Medical Center, Pediatrics, Allergy & Immunology

📍 DURHAM, NC

Score 22 trials

View all T-cell immunodeficiency with thymic aplasia specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰